Cargando…

Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective

BACKGROUND: Approximately 97% of global deaths due to RSV occur in low- and middle-income countries (LMICs). Until recently, the only licensed preventive intervention has been a shortacting monoclonal antibody (mAb), palivizumab (PVZ) that is expensive and intensive to administer, making it poorly s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wittenauer, Rachel, Pecenka, Clint, Baral, Ranju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067246/ https://www.ncbi.nlm.nih.gov/pubmed/37004038 http://dx.doi.org/10.1186/s12916-023-02792-z

Ejemplares similares

Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model
por: Baral, Ranju, et al.
Publicado: (2021)

Cost of illness for childhood diarrhea in low- and middle-income countries: a systematic review of evidence and modelled estimates
por: Baral, Ranju, et al.
Publicado: (2020)

The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models
por: Baral, Ranju, et al.
Publicado: (2020)

Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries
por: Mahmud, Sarwat, et al.
Publicado: (2023)

Inferring antenatal care visit timing in low- and middle-income countries: Methods to inform potential maternal vaccine coverage
por: Baral, Ranju, et al.
Publicado: (2020)

Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study
por: Do, Lien Anh Ha, et al.
Publicado: (2023)

Bringing Preventive RSV Monoclonal Antibodies to Infants in Low- and Middle-Income Countries: Challenges and Opportunities
por: Ananworanich, Jintanat, et al.
Publicado: (2021)

Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis
por: Laufer, Rachel S., et al.
Publicado: (2023)

Maternal vaccination against RSV can substantially reduce childhood mortality in low-income and middle-income countries: A mathematical modeling study
por: Willemsen, Joukje E., et al.
Publicado: (2023)

Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review
por: Mezei, Alex, et al.
Publicado: (2021)

Assessment of gestational age at antenatal care visits among Kenyan women to inform delivery of a maternal respiratory syncytial virus (RSV) vaccine in low- and middle-income countries
por: Nyiro, Joyce U., et al.
Publicado: (2023)

Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022
por: Fitzpatrick, Meagan C., et al.
Publicado: (2023)

Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study
por: Debellut, Frédéric, et al.
Publicado: (2021)

Economic Costs of Childhood Lead Exposure in Low- and Middle-Income Countries
por: Attina, Teresa M., et al.
Publicado: (2013)

Potential impact and cost-effectiveness of future ETEC and Shigella vaccines in 79 low- and lower middle-income countries
por: Anderson, John D., et al.
Publicado: (2019)

Cost and cost-effectiveness of childhood cancer treatment in low-income and middle-income countries: a systematic review
por: Fung, Alastair, et al.
Publicado: (2019)

Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries
por: Li, Xiao, et al.
Publicado: (2020)

Is it RSV?
por: Ambrose, Christopher S.
Publicado: (2018)

Ranking 93 health interventions for low- and middle-income countries by cost-effectiveness
por: Horton, Susan, et al.
Publicado: (2017)

Potential impact and cost-effectiveness of Shigella vaccination in 102 low-income and middle-income countries in children aged 5 years or younger: a modelling study
por: Anderson, John D, et al.
Publicado: (2023)

Economic costs of childhood stunting to the private sector in low- and middle-income countries
por: Akseer, Nadia, et al.
Publicado: (2022)

Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study
por: Debellut, Frédéric, et al.
Publicado: (2019)

Global molecular diversity of RSV – the “INFORM RSV” study
por: Langedijk, Annefleur C., et al.
Publicado: (2020)

Respiratory Syncytial Virus (RSV) Disease and Prevention Products: Knowledge, Attitudes, and Preferences of Kenyan Healthcare Workers in Two Counties in 2021
por: Nyawanda, Bryan O., et al.
Publicado: (2023)

The cost-effectiveness of hypertension management in low-income and middle-income countries: a review
por: Kostova, Deliana, et al.
Publicado: (2020)

RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2022)

What RSV interventions are in the research pipeline?
por: Duong, Diana
Publicado: (2023)

Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries
por: Atwell, Jessica E., et al.
Publicado: (2022)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
por: Cox, Freek, et al.
Publicado: (2023)

Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries
por: Linde, Mattias, et al.
Publicado: (2015)

An outbreak of RSV infections in a neonatology clinic during the RSV-season
por: Vakrilova, Liliya, et al.
Publicado: (2021)

Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis
por: Hodgson, David, et al.
Publicado: (2020)

Compliance with RSV prophylaxis: Global physicians’ perspectives
por: Anderson, Kari S, et al.
Publicado: (2009)

Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
por: Hause, Anne M., et al.
Publicado: (2017)

Forecasting demand for maternal influenza immunization in low- and lower-middle-income countries
por: Debellut, Frédéric, et al.
Publicado: (2018)

Forecasting Demand for the Typhoid Conjugate Vaccine in Low- and Middle-income Countries
por: Debellut, Frédéric, et al.
Publicado: (2019)

Cost analysis of pediatric intensive care: a low-middle income country perspective
por: Kaur, Amrit, et al.
Publicado: (2021)

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model
por: Kieffer, Alexia, et al.
Publicado: (2022)

1633. Willingness to receive maternal RSV vaccine and infant monoclonal RSV antibody
por: Gidengil, Courtney, et al.
Publicado: (2023)

Effects of Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) in the Perinatal Lamb Model of RSV
por: Derscheid, Rachel J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vprduuqnkj884632hb2mbfiv6f